COLO-PREDICT: Digital Training and Optical Diagnosis of Colorectal Polyps

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorClinique Paris-Bercy

About this trial

Colorectal cancer prevention relies on high-quality colonoscopy and accurate optical characterization of colorectal polyps. Optical diagnosis may allow optimization of management strategies such as resect-and-discard for diminutive polyps, potentially improving efficiency in routine practice.

COLO-PREDICT is a prospective, single-center, observational study designed to evaluate the impact of a structured digital training program (Colo-ID, a digital application for colonic polyp characterisation training) on the accuracy of optical histology prediction of colorectal polyps in real-life clinical practice.

All consecutive adult patients undergoing colonoscopy with at least one detected polyp will be included. Optical prediction of polyp histology will be recorded during the procedure. All polyps will be resected and sent for histopathological analysis according to standard practice. No modification of patient management will occur as part of the study.

The primary objective is to assess the concordance between optical prediction and histopathology before and after implementation of the digital training program. Secondary objectives include evaluation of prediction performance according to polyp characteristics and assessment of potential implications for clinical practice.

Eligibility criteria

Qualifiers

Adults aged ≥18 years

Patients undergoing colonoscopy in routine clinical practice at the participating center

At least one colorectal polyp detected during colonoscopy

Optical histology prediction recorded during the procedure

Disqualifiers

Patients aged <18 years

Refusal/opposition to use of data (if applicable under local regulations)

Missing key study data (e.g., no recorded optical prediction or no histopathology result)

Trial design

Treatments tested in this trial

  • Digital Training Program (Colo-ID)

Treatment groups

1,500 Participants
are divided into 1 treatment group

Sponsors and collaborators